|
| Friday, December 7, 2012 |
|
|
Cytokinetics Announces Presentation of Additional Analyses from Clinical Trials of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced a platform presentation of pharmacokinetic data and pharmacokinetic/pharmacodynamic analyses from three previously-reported clinical trials of tirasemtiv in patients with amyotrophic lateral sclerosis (ALS) at the 23rd International Symposium on ALS and Motor Neurone Diseases (ALS/MND) in Chicago, IL. more info >> |
|
| Friday, November 30, 2012 |
|
|
Cytokinetics to Present Clinical Trial Data Relating to Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that a platform presentation relating to tirasemtiv is scheduled to be presented at the 23rd International Symposium on ALS/MND to be held December 5-7, 2012 at the Sheraton Chicago Hotel and Towers Hotel in Chicago, IL. more info >> |
|
| Thursday, November 29, 2012 |
|
|
Cytokinetics Announces Opening of Third and Final Cohort in ATOMIC-AHF |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the opening to enrollment of the third and final cohort in ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure), the ongoing, international, randomized, double-blind, placebo-controlled Phase IIb clinical trial of an intravenous formulation of omecamtiv mecarbil. more info >> |
|
|
Cytokinetics to Host Research and Development Day on Wednesday, December 12, 2012 |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to host its Research and Development Day on Wednesday, December 12, 2012. more info >> |
|
| Thursday, November 8, 2012 |
|
|
Cytokinetics to Present at the Lazard 9th Annual Healthcare Conference |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the Lazard 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 8:00 AM Eastern Time at the Pierre Hotel in New York, NY. more info >> |
|
| Wednesday, October 31, 2012 |
|
|
Cytokinetics, Incorporated Reports Third Quarter 2012 Financial Results |
| Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and development revenues of $1.7 million for the third quarter of 2012. The net loss for the third quarter was $10.0 million, or $0.07 per basic and diluted share, compared to a net loss of $10.6 million, or $0.15 per basic and diluted share, for the same period in 2011. more info >> |
|
| Monday, October 29, 2012 |
|
|
Cytokinetics Announces Opening of BENEFIT-ALS, A Phase IIb Clinical Trial of Tirasemtiv (CK-2017357) in Patients with Amyotrophic Lateral Sclerosis |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the company has opened BENEFIT-ALS (Blinded Evaluation of Neuromusclar Effects and Functional Improvement with Tirasemtiv in ALS), formerly known as CY 4026, to enrollment. more info >> |
|
| Wednesday, October 24, 2012 |
|
|
Cytokinetics, Inc.: Cytokinetics to Announce Third Quarter Results on October 30, 2012 |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report third quarter results on Tuesday, October 30, 2012 at 4:00 PM Eastern Time. more info >> |
|
| Monday, September 24, 2012 |
|
|
Cytokinetics Announces Its Participation in the Launch of MyoKardia Through a Research Collaboration Directed to Hypertrophic Cardiomyopathies |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is participating in the launch of MyoKardia, Inc., a start-up company that is focused to genetic heart disease. more info >> |
|
| Wednesday, September 12, 2012 |
|
|
Cytokinetics Congratulates Its Founders, James A. Spudich, Ph.D. and Ronald D. Vale, Ph.D., on their Receipt of the 2012 Lasker Award for Basic Medical Research |
| Cytokinetics, Incorporated (Nasdaq: CYTK) extends congratulations to Dr. James Spudich and Dr. Ronald Vale, winners of the 2012 Albert Lasker Award for Basic Medical Research. more info >> |
|
|
|
